Renal sarcoid-like granulomatosis during anti-TNF therapy

Morgane, Villemaire; Jean-Charles, Cartier; Nicolas, Mathieu; Maurizi, Jocelyne; Pinel, N.; Bruno, Benedetto; Philippe, Z.; Pierre-Louis, Carron

doi:10.1038/ki.2013.452

Cited by 12 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The other 33 cases required systemic corticosteroid treatment, and the sarcoidosis resolved in 32 cases, but it remained stable in 1 case. In 9 of the 85 patients, the anti-TNF-α agents were continued with systemic corticosteroid treatment, and the sarcoidosis improved in all 9 cases ( 7 , 12 , 18 , 22 , 24 , 39 , 46 , 50 , 57 ). In two cases in which sarcoidosis developed during etanercept treatment, switching from etanercept to adalimumab resulted in regression of sarcoidosis ( 36 , 45 ).…”

Section: Discussionmentioning

confidence: 99%

Systemic Sarcoidosis Associated with Certolizumab Pegol Treatment for Rheumatoid Arthritis: A Case Report and Review of the Literature

et al. 2020

View full text Add to dashboard Cite

A 69-year-old woman presented with appetite loss, fatigue, and a low-grade fever. She had been receiving certolizumab pegol for rheumatoid arthritis for six years. Computed tomography of the chest showed multiple micronodules in both lungs and bilateral hilar and mediastinal lymphadenopathy. An ophthalmic examination showed the findings of uveitis. Lymphocytosis with an increased CD4/CD8 ratio was seen in the bronchoalveolar lavage fluid. Video-assisted thoracoscopic biopsy specimens obtained from the right lung and a right hilar lymph node showed noncaseous epithelioid cell granulomas. Anti-tumor necrosis factor-α-induced sarcoidosis was diagnosed, and she was successfully treated with cessation of certolizumab pegol and systemic corticosteroid therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Systemic Sarcoidosis Associated with Certolizumab Pegol Treatment for Rheumatoid Arthritis: A Case Report and Review of the Literature

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Treatment options for the underlying inflammatory disease, such as AS or RA, poses a clinical dilemma. Sarcoid-like granulomatosis has been reported with both TNF soluble receptors and monoclonal TNF antibodies [ 2 , 4 , 5 ]. Conversely, infliximab, adalimumab and etanercept have all been successfully used as alternative rheumatological therapies in patients who have recovered from GIN [ 7 ].…”

Section: Discussionmentioning

confidence: 99%

Granulomatous interstitial nephritis secondary to adalimumab therapy

Sandys

Moloney

Lane

et al. 2017

Clinical Kidney Journal

View full text Add to dashboard Cite

Tumour necrosis factor α (TNF-α) inhibitors are frequently used for the treatment of immune-mediated diseases. Conversely, cytokine therapy has the potential to paradoxically induce autoimmunity. A number of case reports have emerged concerning sarcoid-like granulomatosis secondary to TNF-α therapy, an adverse effect that typically affects the pulmonary and cutaneous systems. Granulomatous interstitial nephritis (GIN) is a relatively unknown, relatively under-reported consequence of adalimumab therapy that can have important clinical implications. To our knowledge, this is the first case report of GIN secondary to anti-TNF-α therapy necessitating a prolonged period of dialysis and the first report demonstrating the successful use of secukinumab as an alternative immunomodulatory agent.

show abstract

“…Patients with rheumatoid arthritis (RA), psoriasis and inflammatory bowel disease (IBD), that revealed glomerular damage because of TNF-α inhibitors were not included in this review because they have been previously reported elsewhere. [1][2][3][4] We also analyzed studies dealing with renal involvement as a clinical manifestation of SpA, irrespectively of anti-TNF-α treatment.…”

Section: Introductionmentioning

confidence: 99%

Glomerulonephritis in Two Patients with SpA Treated with TNF-α Blockers and a Review of the Literature

Bounia

Theodoropoulou

Liossis

2021

BTT

View full text Add to dashboard Cite

Renal failure or acute/chronic kidney damage may present as a clinical manifestation of rheumatic diseases. In addition treatment with DMARDs or biologic drugs may induce nephrotoxicity. In this case-based review, we present two patients with SpA under anti-TNF-α treatment admitted to our hospital because of renal failure and proteinuria. We review previously published yet isolated cases of TNF-α blocker-induced glomerular disease in patients with SpA. Renal manifestations are occasionally seen in patients with ankylosing spondylitis and psoriatic arthritis with IgA nephropathy being the most common of them. Anti-TNF-α agents although reportedly used for the treatment of glomerular nephropathy as a disease manifestation, they have been considered responsible for provoking renal damage in some cases. A diagnostic approach for patients with SpA treated with anti-TNF-α agents presenting with renal manifestations is proposed herein.

show abstract

Renal sarcoid-like granulomatosis during anti-TNF therapy

Cited by 12 publications

References 0 publications

Systemic Sarcoidosis Associated with Certolizumab Pegol Treatment for Rheumatoid Arthritis: A Case Report and Review of the Literature

Systemic Sarcoidosis Associated with Certolizumab Pegol Treatment for Rheumatoid Arthritis: A Case Report and Review of the Literature

Granulomatous interstitial nephritis secondary to adalimumab therapy

Glomerulonephritis in Two Patients with SpA Treated with TNF-α Blockers and a Review of the Literature

Contact Info

Product

Resources

About